The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases

Expert Review of Clinical Immunology

Volumn 3, Issue 5, 2007, Pages 773-780

  Zandman Goddard, Gisele ^a,b   Krauthammer, Alex ^c   Shoenfeld, Yehuda ^b,d  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; HUMAN ALBUMIN; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; STEROID;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ARTHRITIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; BLISTER; BLOOD PRESSURE; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATOMYOSITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FLUSHING; GUILLAIN BARRE SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFLAMMATORY DISEASE; INFORMATION RETRIEVAL; LOW DRUG DOSE; MALAISE; MEDLINE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 34648823394     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.5.773     Document Type: Review

References (57)

1. Shoenfeld Y. 5th International symposium on IVIG. Autoimmun. Rev. 3, 234-241 (2004).
2. Sherer Y, Levy Y, Langevitz P, Raulova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmtme diseases. Pharmacology 62, 133-137 (2001).
3. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin, adverse effects and safe administration. Clin. Rev. Allergy Immunol. 29, 173-183 (2005).
4. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious disease. Transfus. Med. 12, 133-139 (2002).
5. Zandman-Goddard G, Orbach H, Shoenfeld Y. Novel aproaches to therapy for systemic lupus erythematosus: update 2005. Expert Rev. Clin. Immunol. 1, 223-238 (2005).
6. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin. Rev. Allergy. Immunol. 29, 219-228 (2005).
7. Shoenfeld Y, Krause I. i.v.IG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J. Clin. Immunol. 24, 107-114 (2004).
8. Sherer Y, Shoenfeld Y. Intravenous immunoglobulins for immunomodulation of systemic lupus erytematosus. Autoimmun. Rev. 5, 153-I55 (2006).
9. Pyne D, Ehrenstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmtme rheumatic disease. Rheumatology 41, 367-374 (2002).
10. Braun-Moscovici Y, Furst D. Immunoglobulin for rheumatic diseases in the 21st Century: take it or leave it? Curr, Opin. Rheumatol. 15, 237-245 (2003).
11. Van der Meche FG, Van Doorn PA. Guillain-Barre syndrome. Curr. Treat. Options. Neurol. 2(6), 507-516 (2000).
12. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet 369, 587-596 (2007).
13. Hahn AF. Intravenous immunoglobulin treatment in peripheral nerve disorders - indications, mechanisms of action and side-effects. Curr. Opin. Neurol. 13(5), 575-582 (2000).
14. Levy Y, Uziel Y, Zandman-Goddard G et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann. NY Acad. Sci. 1051, 779-786 (2005).
15. Cervera R, Asherson RA, Font J. Catastrophic antiphospholipid syndrome. Rheum. Dis. Clin. N. Am. 32, 575-590 (2006).
16. Tincani A, Branch W, Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12, 524-529 (2003).
17. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68, 837-841 (2007).
18. Levy Y, Sherer Y, Langevitz P et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report. Clin. Rheumatol. 19, 207-211 (2000).
19. Amital H, Rewald E, Levy Y et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann. Rheum. Dis. 62, 175-177 (2003).
20. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93 (7), 433-439 (2000).
21. Levy Y, Sherer Y, George J et al. Intravenous immtmoglobulin treatment of lupus nephritis. Sem. Arthritis Rheum. 29(5), 321-327 (2000).
22. Orange JS, Hossny EM, Weller CR et al. Use of intravenous immunoglobulin in human disease' a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy; Asthma and Immunology. J. Allergy Clin. Immunol. 117, S525-S553 (2006).
23. Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin. Rev. Allergy Immunol. 29, 185-199 (2005).
24. Park-Min KH, Serbina NV, Yang W et al. FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin. Immunity 26, 4-6 (2007).
25. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney - a two-edged sword. Sem. Arthritis Rheum. 34, 593-601 (2004).
26. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (MG) therapy. Autoimmun. Rev. 4, 257-259 (2007).
27. Levy Y, Sherer Y, Ahmed A, Langevitz P et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serological response. Lupus 8, 705-712 (1999).
28. Arnal C, Piette JC, Leone J et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J. Rheumatol. 29, 75-83 (2002).
29. Tomer Y, Schoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. J. Clin. Exp. Rheumatol. 10, 391-393 (1992).
30. Sherer Y, Levy Y, Langevitz P, Lorber Y, Fabrizzi F, Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin. Rheumatol. 18, 170-173 (1999).
31. Ben-Chetrit E, Putterman C, Naparstek Y. Lupus refractory pleural effusion: transient response to intravenous immunoglobulins. J. Rheumatol. 18, 1635-1637 (1991).
32. Sherer Y, Levy Y, Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin. Rheumatol. 18, 238-240 (1999).
33. Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cydophosphamide for proliferative lupus nephritis. Lancet 354, 569-570 (1999).
34. Zandman-Goddard G, Krauthammer A, Shoenfeld Y. The steroid-sparing effect of IVIG. In: Abstracts of 5th International Congress on Autoimmunity. Shoenfeld Y, Gershwin ME (Eds). Elsevier, The Netherlands 236 (2006).
35. Blank M, Gisondi P, Mimouni D et al. New insights into the autoantibody-mediated mechanisms of autoimmune bullous diseases and urticaria. Clin. Exp. Rheumatol. 24(1 Suppl. 40), S20-S25 (2006).
36. Sarai N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch. Dermatol. 138(9), 1158-1162 (2002).
37. Baum S, Scope A, Barzilai A, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. J. Eur. Acad. Dermatol. Venereol. 20, 548-552 (2006).
38. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J. Am. Acad. Dermatol. 45, 679-690 (2001).
39. Mittmann N, Chan B, Knowles S, Mydlarski PR, Cosentino L, Shear N. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J. Cutan. Med. Surg. 10, 222-227 (2006).
40. Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 39(7), 601-607 (2006).
41. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J. Am. Acad. Dermatol. 45(6), 825-835 (2001).
42. Sanai N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur. J. Dermatol. 12(2), 174-178 (2002).
43. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin rherapy in relapsing-remitring multiple sclerosis. Austrian Immunoglobulin in Multiple sclerosis Study Group. Lancet 349, 589-593 (1997).
44. Sorensen PS, Wanscher B, Schreiber K, Blinkenberg M, Jeusen CV, Ravnborg M. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult. Scler. 3, 145-148 (1997).
45. Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50, 398-402 (1998).
46. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M; TARIMS Study Group. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63, 2028-2033 (2004).
47. Visser LH, Beekman R, Tijssen CC et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult. Scler. 10, 89-91 (2004).
48. Gedalia A, Correa H, Kaiser M, Sorensen R. Case report: steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis. Aro. J. Med. Sci. 309(4), 226-228 (1995).
49. Kurz D, Egan RA, Rosenbaum JT. Treatment of corticosteroid dependent optic neuropathy with intravenous immunoglobulins. Am. J. Ophthalmol. 140(6), 1132-1133 (2005).
50. Onal S, Foster S, Ahmed R. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocular Immunol. Inflamm. 14, 376-374 (2007).
51. Blank M, Nur I, Toub O, Maor A, Shoenfeld Y. Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin. Rev. Allergy Immunol. 29(3), 213-217 (2005).
52. Krause I, Blank M, Shoenfeld Y. Anti-DNA and anti-phospholipid antibodies in IVIG preparations: in vivo study in nasive mice. J. Clin. Immunol. 18, 52-60 (1998).
53. Silvestris F, Cafforio P, Dammacco F. Pathogenic and anti-DNA idiotype reactive IgG in intravenous immunoglobulin preparations. Clin. Exp. Immunol. 97, 19-25 (1994).
54. Caccavo D, Vaccaro F, Ferri GM et al. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J. Autoimmun. 7, 534-548 (1994).
55. Evans M, Abdou NI. In vitro modulation of and-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin. Lupus 2, 371-375 (1993).
56. Shoenfeld Y, Rauova L, Gilburd B et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immnuol. 14, 1303-1311 (2002).
57. Blank M, Anafi L, Zandman-Goddard G et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. 19(7), 857-865 (2007).